Radiofrequency ablation (RFA) of Barrett ' s esophagus (BE) is safe and effective in eradicating dysplasia and intestinal metaplasia, and may reduce rates of esophageal adenocarcinoma (EAC). We assessed rates of and risk factors for disease recurrence after successful treatment of BE with RFA.
INTRODUCTION
Barrett ' s esophagus (BE) aff ects 1 -2 % of the general population ( 1, 2 ) and is the precursor lesion of esophageal adenocarcinoma (EAC), a cancer with a marked increase in incidence over the past four decades ( 3 -5 ) . Endoscopic ablative therapy is frequently performed to treat dysplastic BE with the aim of permanently eliminating dysplasia and intestinal metaplasia (IM) to prevent neoplastic progression. Recent studies of radiofrequency ablation (RFA) for BE with dysplasia have demonstrated that RFA is safe and eff ective, with low complication rates, high rates of complete eradication of dysplasia (CE-D) and intestinal metaplasia (CE-IM), and a potential decrease in progression to cancer ( 6 -9 ) .
Although RFA safely and eff ectively eradicates dysplasia and IM, the durability of the neosquamous epithelium that regenerates is not well understood. Th is is especially true of subjects with the most severe disease, those with high-grade dysplasia (HGD), and those with intramucosal carcinoma (IMC) . Th e few studies that report on the durability of successful response to treatment with RFA are limited by small sample sizes and short periods of followup ( 10 -15 ) . A recent multicenter, randomized, sham-controlled trial reported on the durability of RFA in dysplastic BE and found that dysplasia remained eradicated in > 85 % of patients and IM in > 75 % of patients aft er 3 years, without RFA re-treatment ( 16 ) . However, only 54 of the 106 subjects in this trial had HGD; the remainder had low-grade dysplasia (LGD) .
Th e aim of this study was to determine rates of disease recurrence and progression following successful eradication of dysplasia and IM in BE with dysplasia or IMC following RFA therapy. We also sought to determine factors associated with disease recurrence following CE-IM.
METHODS

Patient eligibility and data collection
We performed a retrospective study of adult patients who completed RFA therapy for BE with LGD, HGD, or IMC and underwent subsequent endoscopic surveillance at the University of North Carolina (UNC) Hospitals between 2006 and 2011. Subjects who received an upper endoscopy (EGD) with RFA between 1 January 2006 and 1 November 2011 were identifi ed by review of our electronic endoscopic database (Provation MD, Wolters Kluwer, Minneapolis, MN). One of two investigators (HK, WB) then reviewed each subject using the electronic medical record (WebCIS, UNC Health Care System) to determine eligibility for inclusion. All institutional health information and imported external records were abstracted. Patients were excluded if they never had treatment with RFA; were treated with RFA for a non-BE-related disease; did not have a pre-ablation histology of LGD, HGD or IMC; did not complete RFA therapy; or did not enter surveillance at UNC Hospitals with CE-D or CE-IM. Patients were considered to be under surveillance if they received at least one EGD aft er a post-RFA EGD demonstrated CE-D or CE-IM. All eligible patients were included in the surveillance cohort and were examined to determine durability of response to RFA treatment.
Pertinent data were extracted from clinical, endoscopy, and pathology reports for each subject and included demographic information (age, gender, race, and body mass index), pertinent medical history (erosive esophagitis and peptic stricture), substance use (alcohol and tobacco), medication use (anti-secretory therapy and non-steroidal anti-infl ammatory drugs), EGD fi ndings (length of BE, hiatus hernia, erosions, ulcers, and nodules), pre-ablation histology, treatment provided, ablation outcomes, and durability outcomes.
Pretreatment evaluation and procedural protocol
All patients had an initial consultation visit to discuss BE and dysplasia, its risk of progression to cancer, and the risks and benefi ts of diff erent treatment options including continued endoscopic surveillance, ablative therapy, and, in the case of HGD or IMC, esophagectomy. Before the fi rst visit, the worst histological grade of BE was determined by review of original pathology records. An expert gastrointestinal pathologist reviewed all cases, and if fi ndings between the initial pathology report and the secondary review were discordant, an additional expert gastrointestinal pathologist reviewed the case with histological classifi cation by consensus.
Patients with BE and LGD were off ered RFA followed by endoscopic surveillance, or endoscopic surveillance alone. Patients with BE and HGD or IMC were off ered RFA followed by endoscopic surveillance, esophagectomy, or, in the case of HGD, endoscopic surveillance alone. Patients with BE and HGD or IMC who opted for RFA had pretreatment staging by EGD and endoscopic ultrasound to exclude invasive disease (submucosal infi ltration, lymph node, or metastatic spread) that would preclude curative endoscopic treatment. If the BE segment contained nodularity, endoscopic mucosal resection (EMR) was performed before beginning the RFA therapy. Nodules were defi ned endoscopically as any contoured irregularity and elevation of the mucosa without breaks, including Paris classifi cation 0 -I and 0 -IIa lesions ( 17 ) . All resections were performed using either the Olympus 18 mm oblique cap kit (Olympus America, Center Valley, PA) or the Duette device (Cook Medical, Winston-Salem, NC). EMR performed with the Olympus device was preceded by submucosal injection of saline, whereas EMR with the Duette device was performed without prior injection. If the BE segment was not nodular, RFA was performed as outlined below. RFA therapy was initiated 2 months aft er all nodular lesions were removed by EMR, and if pathology specimens did not reveal submucosal infi ltration of EAC. Twice daily proton pump inhibitor therapy was prescribed to all patients before and throughout RFA treatment.
RFA was performed using the HALO 360 device (BARRX Medical, Sunnyvale, CA, USA) for circumferential disease and the HALO 90 device for focal lesions. Standard procedural technique was used as previously described ( 8 ) . Patients returned every 2 months for repeat EGD to assess treatment response. EMR was performed if patients developed nodular disease during the treatment period. Patients with non-nodular residual disease underwent focal RFA treatment. Treatment was continued in this manner until no visible BE was observed on white light and narrow-band imaging endoscopy. At this point, treatment was considered complete and four-quadrant biopsies were taken from just distal to the gastroesophageal junction and at 1-cm intervals along the length of the original BE segment. Subjects were then off ered continued endoscopic surveillance to monitor their condition, either at our institution, or, for those not living locally, follow-up with their referring gastroenterologist.
Th e date of these esophageal biopsies marked the " index date, " the date when the surveillance period began. Surveillance EGDs at our institution were performed using narrow-band imaging and four-quadrant biopsies just distal to the gastroesophageal junction and at 1-cm intervals along the length of the original BE segment. Separate biopsy samples were obtained for any visible BE during surveillance. Patients who had pre-ablation LGD received surveillance EGDs every 6 months for 1 year, and if patients were disease-free aft er 1 year, they were followed up annually thereaft er. 
Outcomes and statistical analysis
Upon completion of therapy, all biopsy specimens were analyzed by an expert gastrointestinal pathologist to assess for the presence of residual BE and degree of dysplasia. Any reading of dysplasia was subsequently confi rmed by a second histological analysis by an expert gastrointestinal pathologist. Outcomes upon treatment completion included CE-D and CE-IM. CE-D was defi ned as the absence of dysplasia from all esophageal biopsies, and CE-IM was defi ned as complete endoscopic resolution with the absence of IM from all esophageal biopsies. Th roughout the surveillance period, biopsy specimens were similarly examined to determine the presence of any recurrent IM or dysplasia.
Two separate cohorts were analyzed: patients that achieved CE-D (with or without CE-IM) and the subset of patients that achieved CE-IM. Primary durability outcomes included recurrent disease and progressive disease. For the CE-IM cohort, recurrent disease was defi ned as any recurrence of IM with or without dysplasia. For the CE-D cohort, recurrent disease was defi ned as recurrence of any grade of dysplasia, not including non-dysplastic (ND) BE. Progressive disease was defi ned as recurrence at a worse level than pretreatment histology. As patients actively under surveillance are scheduled to undergo EGD at least yearly, those who had not undergone an EGD within the 15 months before the conclusion of this study were considered lost to follow-up. Th e characteristics and clinical courses of each patient with recurrent disease were described.
Statistical analysis was performed using Stata soft ware (version 12.0; StataCorp LP, College Station, TX, USA). Descriptive statistics were performed for patients entering the surveillance period upon achieving CE-IM. Categorical variables were reported as counts and percentages. Continuous variables were reported as means and s.d ' s or medians and interquartile ranges for nonnormally distributed variables. Comparisons between groups were performed using Fisher ' s exact test for categorical variables and Student ' s t -test or Wilcoxon rank-sum test for continuous variables. Kaplan -Meier survival analyses were performed to determine the rates of disease recurrence. For these Kaplan -Meier analyses of dysplasia-free and intestinal metaplasia-free survival, any recurrent dysplasia or IM, respectively, was considered a failure, even if subsequent RFA resulted in a recurrent complete eradication. Comparisons between rates were performed using the log-rank test. Th e UNC Institutional Review Board approved this study.
RESULTS
In all, 262 patients received RFA for BE during the study period. Of these, 244 had a pretreatment diagnosis of either dysplastic BE or IMC. Of 188 patients who completed treatment for BE with dysplasia or IMC, 183 achieved CE-D, and 168 achieved CE-IM ( Figure 1 ). Within these groups, 119 and 112 patients entered endoscopic surveillance, respectively, at our institution, with the remainder opting to undergo surveillance with their local gastroenterologist due to proximity. Subjects returning to their referring gastroenterologist for surveillance were not signifi cantly diff erent from those pursuing surveillance at UNC with respect to demographics or pretreatment histology. Baseline characteristics of the 112 patients who achieved CE-IM and underwent surveillance are reported in Table 1 . Th e mean age was 64.1 ± 10.9 years, 79.5 % were male, 111 of the 112 (99.1 % ) patients were Caucasian, and the mean length of BE was 4 cm. Patients with IMC were more likely to have had pre-ablation erosive esophagitis or to have received EMR at any time. Patients underwent a mean of 3.0 ± 1.5 RFA sessions, and 63.4 % received circumferential therapy. Patients were followed in surveillance for a median of 397 days (range 54 -1,668). Five patients were lost to follow-up.
In those under endoscopic surveillance following CE-D and CE-IM, an analysis of durability was performed using KaplanMeier estimation. As demonstrated in Figure 2a , of the 119 patients who attained CE-D and enrolled in endoscopic surveillance at our institution, 85 % of patients remained free of dysplasia at a median follow-up of 393 days with no additional therapy. Dysplasia did not recur in any subject treated for LGD; in those treated for HGD or IMC, dysplasia recurred in 4.2 % per year ( Figure 2b ) , with a median time to recurrence of 173 days. All fi ve recurrences of dysplasia were among those who had achieved CE-IM with RFA. Of the 112 patients followed aft er CE-IM, 80 % remained free of IM ( Figure 3a ) . Only one patient with pre-ablation LGD had recurrent IM (2.4 % per year), whereas fi ve with pre-ablation HGD and two with pre-ablation IMC had recurrent IM (5.5 % per year and 9.4 % per year, respectively) ( Figure 3b ). Among patients experiencing IM recurrence, IM recurred at a median of 235 days into surveillance (range 55 -1,124).
Among the eight patients who experienced recurrence of IM following CE-IM, most had a benign clinical course ( Table 2 ). In fi ve of these patients, the histological grade at the time of recurrence was at or below the pretreatment grade. Of these, three had histological recurrence, but no endoscopic evidence of recurrent BE. One of the other two patients had an " irregular z-line " only, and the other had a small isolated island of BE. In all of these cases, the pathologist described the histological recurrence as " sparse, " " minute, " or within " one fragment " . In no case was the recurrent BE noted to be sub-squamous. Th ree of the eight patients experiencing recurrence of IM were re-treated with RFA for NDBE ( n = 1), LGD ( n = 1) and HGD ( n = 1), and all subsequently had CE-IM. Th e two other patients who experienced recurrence but not progression had NDBE at recurrence and continued endoscopic surveillance.
All three patients who had histological progression (i.e., grade at the time of recurrence greater than the pretreatment grade) had pretreatment HGD. One developed a single, visible, 5-mm island of IMC, which was successfully treated with EMR. Another developed IMC within an endoscopically normal-appearing gastroesophageal junction and shortly thereaft er progressed to EAC, LGD, low-grade dysplasia; NSAID, non-steroidal anti-infl ammatory drug; PPI, proton pump inhibitor; RFA, radiofrequency ablation .
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DISCUSSION
Endoscopic RFA is an established safe and eff ective therapy for dysplastic BE and results in a high proportion of CE-D and CE-IM. However, the durability of CE-IM following treatment, especially for subjects with more severe disease (HGD and IMC), is not clear. Th is study demonstrates that the majority of patients successfully treated with RFA for dysplastic BE or IMC maintain CE-IM aft er more than a year of follow-up. Of those who developed recurrent IM, most were not histologically worse than the pretreatment grade and the area of recurrence was generally small. More than half were in the setting of an endoscopically normal-appearing esophagus or irregular z-line. Th is study is the largest to date reporting RFA outcomes and durability in subjects with HGD and IMC. However, several studies have examined the risk of IM recurrence following successful RFA for dysplastic BE ( Table 4 ). Pouw et al. ( 10 ) demonstrated that among 43 patients who achieved CE-IM following RFA for HGD or early cancer, 5 (12 % ) had histological recurrence immediately distal to a normal-appearing neosquamous columnar junction during a median follow-up of 21 months. Only one had endoscopic which was subsequently treated successfully with esophagectomy. One had an acute MI just before his scheduled yearly endoscopy, which was therefore cancelled. He became symptomatic from a fungating esophageal mass 20 months aft er his prior negative endoscopy and was subsequently diagnosed with metastatic EAC. He died aft er systemic chemotherapy and radiation. During 155 total years of observation, the rate of any recurrence was 5.2 % per year, the rate of recurrence with HGD or worse histology was 2.6 % per year, the rate of recurrence with EAC was 1.3 % per year, and the rate of death from EAC was 0.6 % per year.
In bivariate analyses, we assessed a variety of clinical, endoscopic, and treatment variables as predictors of recurrence following CE-IM. Patients with recurrence of IM were not statistically diff erent in these characteristics from those who did not recur in bivariate analysis ( Table 3 ). However, numerically, patients with recurrence were younger, with a higher BMI, and with a longer BE length. Th ey were also more likely to have had an esophageal stricture, erosive esophagitis, a medium or larger hiatal hernia, and a pre-ablation histology of IMC. Multivariate analysis could not be performed due to the small number of recurrences. LGD, low-grade dysplasia; HGD / IMC, high-grade dysplasia / intramucosal carcinoma. recurrence, and none had recurrent dysplasia. In two series, Gondrie et al. ( 18, 19 ) reported no visible recurrence among 23 patients with CE-IM following RFA for dysplastic BE. One patient had recurrence of focal IM just distal to the neosquamous columnar junction. In a multicenter trial of RFA for HGD or early cancer, 23 of 24 patients achieved CE-IM with EMR and RFA ( 12 ) . Twenty-three of these patients received EMR before RFA, and two required salvage EMR aft er RFA to obtain CE-IM. Only three patients (13 % ) who achieved CE-IM had recurrence of IM at 22 months of median follow-up. Again, there was no recurrent dysplasia. Th e same group reported two endoscopic and three histological recurrences without dysplasia among 19 patients (26 % ) who achieved CE-IM aft er RFA of BE segments ≥ 10 cm ( 13 ). Mean follow-up was 21 months aft er treatment completion. In a randomized trial of RFA vs. EMR for HGD or early cancer, none of 21 patients who had achieved CE-IM had endoscopic recurrence aft er a median 15 months of follow-up ( 14 ) . Four patients had histological recurrence without dysplasia at the neosquamous columnar junction. Two of these were within single biopsy specimens and were not reproduced on subsequent endoscopies. Vaccaro et al. ( 15 ) reported recurrent IM in 15 of 47 patients (32 % ) who had achieved CE-IM following RFA at a single center. Median follow-up in this study was 13.3 months. Four of these recurrences had dysplasia (two LGD and two HGD) at the neosquamous columnar junction, none of which were seen endoscopically, and one represented progression from LGD to HGD. In bivariate analysis, a longer baseline BE segment was associated with IM recurrence. Th ree-year follow-up of a randomized controlled trial of RFA for dysplastic BE showed recurrent IM in 14 of 108 patients who achieved CE-IM ( 16 ) . Seven of the 14 had recurrence at a normal or irregular z-line. Th e other seven consisted of small, isolated islands ( n = 3) or tongues ( n = 4). Among the patients with recurrence, only 3.8 % of biopsies demonstrated IM. Th is study compares favorably with prior studies in that ≥ 80 % were able to maintain CE-D and CE-IM without additional therapy. Moreover, the recurrence rate of 5.2 % per year is lower than the calculated rates for the previous studies ( Table 4 ). As in the other studies, recurrence was typically minimal, with little endoscopic evidence of recurrence and few positive biopsies in most cases. In addition, the majority of patients with recurrent IM had uneventful clinical courses. Six (75 % ) of our recurrences were successfully re-treated endoscopically or kept under surveillance. Nevertheless, despite our overall good outcomes, one patient required esophagectomy aft er progressing to EAC, and one progressed to metastatic EAC. Th e former patient had a large hiatal hernia but no endoscopic evidence of recurrence despite the IMC ESOPHAGUS Durability of RFA for Barrett ' s Esophagus in this patient population. As suggested by Vaccaro et al. ( 15 ) , the neosquamous columnar junction may be an area at risk for the development of dysplasia or adenocarcinoma. However, the optimal method to prevent such progression is not clear.
Due to the small number of recurrences, we were unable to determine predictors of recurrence or progression. However, the median pre-RFA BE length was numerically greater among those who had recurrence (7 vs. 4 cm, P = 0.2). Furthermore, the two patients who progressed to EAC had among the longest BE segments in the cohort. Vaccaro et al. ( 15 ) found that the baseline BE length was signifi cantly longer in those who developed recurrence. Th e reasons for such an association are unclear, but longer length may be a marker of more severe refl ux, or may be a surrogate measure of the likelihood of harboring a more genetically advanced dysplastic clone. Th ere does not appear to be an increased risk of recurrence for patients who achieve CE-D without CE-IM, as none were seen in this study. However, the small number of patients in this group ( n = 7) prevents a fi rm conclusion on this matter. Larger studies are needed to identify predictors of recurrence, which would be valuable to risk stratify patients aft er ablation to better target surveillance eff orts.
Th is study has several limitations. As with other studies on this topic, sampling error is a concern. Although this cohort was found to have CE-IM on biopsy, it is conceivable that residual IM (especially sub-squamous or " buried " IM) might be missed and that patients who never achieved true CE-IM were included in the cohort due to sampling error. In such an instance, subsequent biopsies showing IM would incorrectly classify a patient as recurrent disease when they should have been considered an incomplete initial treatment. Such an error would have the eff ect of infl ating our cohort size at the cost of increasing the recurrence rate. One-third of patients who achieved CE-IM returned to their referring physician for surveillance aft er treatment completion and were therefore not available for follow-up. A diff erence in recurrence rate between this group and our cohort would bias our recurrence estimate. However, the pretreatment histology of those receiving follow-up locally was not diff erent from those continuing at our institution, decreasing the concern that baseline diff erences between the groups might lead to a biased estimate of disease recurrence. Additionally, it is common that recurrence in this group prompts re-referral to our center for management. Th erefore, if such a bias exists, it likely results in an overestimate of recurrence. Given that this is a single-center study, the generalizability of our fi ndings, especially to practice settings with lower volumes of cases, is unclear. It should be noted, however, that similar results have been reported in a cohort of subjects treated in community practice ( 7 ) . Other limitations of this study include the small number of recurrences that prevents identifi cation of predictors of recurrence, as well as its retrospective nature.
In this study of patients with CE-IM following RFA of dysplastic BE, we found a low rate of IM and dysplasia recurrence. Among those with recurrent IM, most had a benign course, although three cases exhibited progressive disease. One subject, who was unable to attend surveillance endoscopy, developed and died from metastatic EAC. Due to the small number of recurrences, we did not identify any statistically signifi cant predictors of recurrence. seen histologically at the gastroesophageal junction. As described above, the latter patient missed surveillance endoscopy due to a cardiac event, but the prior surveillance endoscopy (20 months before his diagnosis of metastatic EAC) showed a normal z-line without histological abnormality. Th ese two patients each had 9 cm of pre-ablation IM (90th percentile), but were otherwise without specifi c features in their pre-recurrence clinical course that would distinguish them from the remainder of the cohort. Cases such as these reinforce the need for continued surveillance In general, these results should serve to reassure patients and their physicians that, in most cases, RFA induces a durable complete eradication of dysplasia and intestinal metaplasia. At the same time, the few cases of progression point to the need for continued surveillance following treatment. Further follow-up of this cohort and others is needed to identify predictors of IM recurrence so that continued surveillance can be appropriately targeted to the highest risk patients.
